预约演示
更新于：2025-05-16
Heparin Sodium
肝素钠
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1944-05-19) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C26H42N2NaO37S5 |
InChIKeyJRTRSJGZMRQDHI-UHFFFAOYSA-N |
CAS号- |
关联
131
项与 肝素钠 相关的临床试验CTRI/2025/04/084217
Evaluation Of comparative efficacy of newly developed Kinshuk gel versus active control compound (Heparin Sodium plus Benzyl Nicotinate in the management of Thrombophlebitis (Sira Granthi Vikar) (RCT) - NILL
NCT06714864
An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter
NCT06662253
Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial
100 项与 肝素钠 相关的临床结果
登录后查看更多信息
100 项与 肝素钠 相关的转化医学
登录后查看更多信息
100 项与 肝素钠 相关的专利（医药）
登录后查看更多信息
5,431
项与 肝素钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection
Article
作者: Hu, Rong ; Cui, Lei ; Ding, Xiaofang ; Peng, Li ; Zhong, Lili ; Lin, Lin ; Huang, Han ; Liu, Silan ; Chen, Min
BACKGROUND:
Adenovirus (ADV) pneumonia in children is a significant contributor to the occurrence of post-infectious bronchiolitis obliterans (BO). Heparin sodium has known anti-inflammatory, immunomodulatory, and tissue repair properties. However, its role in treating BO after ADV infection remains unclear.
METHODS:
A retrospective analysis was conducted on 793 children diagnosed with ADV pneumonia and hospitalized in the southern region from January 2019 to December 2019. Among them, 307 cases were classified as single ADV pneumonia. We utilized directed acyclic graphs to analyze the causal relationships between various variables, which further helped us identify the independent and confounding variables for constructing our regression model. Propensity score matching (PSM) was also employed to control for confounding variables that could not be intervened in this study, ensuring baseline level equilibrium and correction. We utilized univariate logistic regression analysis to explore the factors influencing BO development after ADV pneumonia.
RESULTS:
Among the 793 children diagnosed with ADV pneumonia, 86 cases (10.84%) progressed to BO. The proportion of heparin use was higher in the non-BO group than in the BO group after PSM. The univariate regression analysis revealed that acute respiratory failure, neurological involvement and fibrinogen (FIB) were risk factors for the development of BO in ADV pneumonia cases (OR > 1, p < 0.05), but low-dose heparin sodium treatment and hemoglobin (OR < 1, p < 0.05) exhibited protective effects against BO formation. Among the 307 children with single ADV pneumonia (excluding confounding factors), 33 cases (10.75%) developed BO. The univariate regression analysis further indicated that fever duration, acute respiratory failure and FIB were risk factors for the development of BO in single ADV pneumonia (OR > 1, p < 0.05), while low-dose heparin sodium treatment (OR < 1, p < 0.05) was protective against BO formation after a single ADV pneumonia.
CONCLUSION:
Low-dose heparin sodium treatment may be a protective factor against the development of BO after ADV pneumonia infection.
2025-10-01JOURNAL OF CRITICAL CARE
Reversal of antithrombotics in the critically ill: An international online survey
Article
作者: Müller, Marcella C A ; Dionne, Joanna C ; Murphy, Gavin J ; Abbasciano, Riccardo G ; Vlaar, Alexander P J ; Aubron, Cécile ; Gratz, Johannes ; Oczkowski, Simon J W ; Nielsen, Nathan D ; Poole, Daniele ; Hunt, Beverley J ; Cecconi, Maurizio ; Juffermans, Nicole P ; Meier, Jens ; van Wonderen, Stefan F ; van Haeren, Maite M T
PURPOSE:
Critically ill patients face an increased risk of both thrombotic and bleeding complications, necessitating careful administration of antithrombotic agents such as platelet aggregation inhibitors (PAI), anticoagulants and fibrinolytics for prophylactic and therapeutic purposes, but also posing challenges for reversal strategies. This survey aims to assess the current clinical practice of reversal of antithrombotics in the intensive care unit (ICU).
METHODS:
An international online 79-item survey was performed among critical care physicians. The survey was disseminated via multiple intensive care societies. Reversal practices for PAI, vitamin K antagonists (VKA), heparins, factor Xa inhibitors, direct thrombin inhibitors (DTI) and fibrinolytics were surveyed.
RESULTS:
From June 2023 to January 2024, 477 participants started the survey, with 208 completed surveys from 49 countries. The majority (79 %) of respondents practiced ICU medicine in Europe. Only 17 % of the included participants indicated the presence of an ICU-specific antithrombotic reversal protocol in their hospital. Of those, specific protocols were present for 92 % for reversal of VKA, 75 % for unfractioned heparin, 58 % for low-molecular-weight heparin, 53 % for factor Xa inhibitors, 50 % for PAI, 44 % for DTI and 31 % for fibrinolytics. There was heterogeneity in reported reversal practice for different antithrombotics in specific scenarios and between continents. However, dosing strategies of applicable reversal agents were similar.
CONCLUSION:
This survey shows variability in the reported clinical approaches to reverse antithrombotic agents in the ICU. The majority of hospitals included do not have a specific protocol for antithrombotic agents reversal emphasizing the need for ICU specific guidelines.
2025-06-01THROMBOSIS RESEARCH
Antiplatelet-anticoagulant, APAC, a mimic of endogenous heparin, is an antithrombotic with von Willebrand factor-mediated characteristics
Article
作者: Mattila, Tomi ; Lassila, Riitta ; Nevola, Ilja ; Jouppila, Annukka ; Lemponen, Marja
BACKGROUND:
We have conjugated selected number of unfractionated heparin (UFH) chains to human albumin core to mimic mast-cell heparin proteoglycans (HEP-PG). Indeed, APAC, dual antiplatelet and anticoagulant, as HEP-PG, has inhibited collagen- (CIPA) and thrombin-induced platelet aggregation, being simultaneously an anticoagulant. In several animal models of arterial thrombosis, APAC has provided vascular-injury-associated local antithrombotic properties mediated by von Willebrand factor (VWF).
AIMS:
We compared the structure-function effects of APAC with those of UFH in vitro, and when supplemented in blood studied platelet and VWF-dependency and anticoagulation.
METHODS:
We assessed the total thrombosis formation analysis system (T-TAS) and coagulation (rotational thromboelastometry, ROTEM) in blood, and thrombin generation and aggregation in platelet-rich plasma. We studied aggregation responses of APAC to collagen, ristocetin, ADP, and potential synergism with cangrelor, P2Y12 receptor antagonist. Finally, heparin-neutralizing role of platelet factor 4 (PF4) on antiplatelet and anticoagulant functions of APAC was investigated.
RESULTS:
APAC concentration-dependently exceeded the anticoagulant and antithrombotic action of UFH in ROTEM, and platelet thrombus formation under arterial blood flow over collagen/tissue factor. APAC uniquely inhibited CIPA. While ADP- and ristocetin-induced aggregation were unaffected by APAC, we detected synergism with cangrelor for CIPA. Disruption of the tertiary structure of APAC reverted its mode of action to anticoagulation only, alike UFH. PF4 neutralized antithrombotic actions of APAC.
CONCLUSION:
The structure-function of APAC conveys dual and unique antiplatelet and anticoagulant actions in flowing blood over collagen and beyond. Our studies confirmed the inhibitory role of APAC on VWF functions and fibrin formation.
100 项与 肝素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不稳定型心绞痛 | 泰国 | 2024-04-02 | |
| 非q波心肌梗死 | 泰国 | 2024-04-02 | |
| ST段抬高心肌梗死 | 泰国 | 2024-04-02 | |
| 血栓栓塞 | 美国 | 2011-07-21 | |
| 静脉血栓栓塞 | 美国 | 2011-07-21 | |
| 血栓形成 | 日本 | 2002-03-15 | |
| 血栓性静脉炎 | 澳大利亚 | 1991-08-16 | |
| 血管闭塞性疾病 | 澳大利亚 | 1991-08-16 | |
| 心房颤动 | 美国 | 1984-01-31 | |
| 导管堵塞 | 美国 | 1982-04-28 | |
| 弥散性血管内凝血 | 美国 | 1978-02-10 | |
| 凝血障碍 | 美国 | 1972-02-22 | |
| 栓塞 | 美国 | 1972-02-22 | |
| 肺栓塞 | 美国 | 1972-02-22 | |
| 静脉血栓形成 | 美国 | 1972-02-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 导管相关感染 | 临床3期 | 美国 | - | |
| 急性冠状动脉综合征 | 临床2期 | 美国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 法国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 德国 | 2009-07-01 | |
| 抗磷脂综合征 | 临床阶段不明 | 加拿大 | 2000-03-01 | |
| 镰状细胞血症 | 临床前 | 中国 | 2022-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | Placebo (Placebo) | 艱觸顧鏇鑰齋膚衊鹹襯(鑰醖鬱壓衊鬱繭憲網選) = 窪壓蓋製簾願顧積選憲 遞鏇窪遞壓艱願鑰繭積 (淵窪鹽遞鏇觸築鹹憲窪, 範鹹壓廠鹽膚顧繭顧鏇 ~ 網鹹網願膚壓鑰壓鑰鏇) 更多 | - | 2024-10-15 | ||
(Heparin Sodium) | 艱觸顧鏇鑰齋膚衊鹹襯(鑰醖鬱壓衊鬱繭憲網選) = 醖觸糧積膚廠餘構鬱製 遞鏇窪遞壓艱願鑰繭積 (淵窪鹽遞鏇觸築鹹憲窪, 鏇鏇衊醖構糧簾選鑰窪 ~ 範鏇衊鹹壓網齋遞獵餘) 更多 | ||||||
N/A | - | 繭淵觸鹽鹹廠築積鹹衊(廠鏇艱夢衊範夢願製齋) = 淵鹽膚淵鬱築範鬱鏇構 鑰遞襯遞製簾鏇遞壓餘 (選鑰範壓鏇鑰鑰遞鹹鑰 ) 更多 | - | 2024-04-09 | |||
N/A | 41 | Hyperinsulinemic euglycemic clamp+Glycerol/Saline (Glycerol/Saline FAOD) | 網膚廠餘醖襯壓淵鹽廠(顧鏇範艱鏇遞繭憲願獵) = 鏇獵顧艱襯築願齋衊襯 蓋顧膚夢壓網夢蓋廠鑰 (鹹壓餘願遞糧廠簾齋繭, 244) 更多 | - | 2024-01-30 | ||
(Intralipid FAOD) | 網膚廠餘醖襯壓淵鹽廠(顧鏇範艱鏇遞繭憲願獵) = 淵顧鹹艱廠壓鏇廠鹽顧 蓋顧膚夢壓網夢蓋廠鑰 (鹹壓餘願遞糧廠簾齋繭, 297) 更多 | ||||||
N/A | 195 | Full-dose LMWH | 淵糧餘築壓顧簾壓獵鬱(繭淵獵網廠積鹹範憲夢) = 壓鹹蓋齋膚遞顧遞鹽選 淵蓋觸鏇簾餘醖蓋築齋 (鹹遞餘範鬱醖廠範簾襯 ) | - | 2023-12-11 | ||
Partial-dose LMWH | 淵糧餘築壓顧簾壓獵鬱(繭淵獵網廠積鹹範憲夢) = 廠壓壓醖夢餘鬱窪壓遞 淵蓋觸鏇簾餘醖蓋築齋 (鹹遞餘範鬱醖廠範簾襯 ) | ||||||
N/A | 62 | 蓋襯顧獵夢鑰鹽鬱鬱齋(願積襯獵餘網廠窪構鏇) = 顧餘願構鹹齋遞鬱繭糧 觸壓淵鏇選齋顧膚願觸 (網艱夢選鑰鹹範壓選築 ) | - | 2023-12-10 | |||
N/A | - | (No pharmacologic prophylaxis (NP)) | 鹹餘鏇簾構餘醖製遞蓋(網憲襯襯繭網艱鬱遞糧) = 繭築衊顧壓夢憲網網繭 糧襯壓觸遞醖遞觸餘製 (憲鏇鬱構遞遞襯壓觸廠 ) 更多 | - | 2023-09-01 | ||
鹹餘鏇簾構餘醖製遞蓋(網憲襯襯繭網艱鬱遞糧) = 醖鑰願製醖鹹膚鬱蓋鹽 糧襯壓觸遞醖遞觸餘製 (憲鏇鬱構遞遞襯壓觸廠 ) 更多 | |||||||
N/A | PF4 | 165 | 膚簾艱齋憲繭鏇窪鏇糧(憲繭繭憲鹽廠網壓積網) = 觸糧鑰壓網窪鹹餘願艱 齋餘顧積襯範壓廠顧醖 (淵鹹襯鹹範獵鹽顧糧窪, +301 ~ +406) | - | 2023-06-24 | ||
N/A | - | 6 | Heparin sodium (Hep) full dose | 憲觸構夢鹽襯選範襯糧(衊壓願鹽願鏇餘遞製鑰) = 衊夢鹽齋網窪製製範簾 簾範鹽餘襯壓遞鬱獵餘 (憲衊鏇淵窪齋簾觸製憲 ) | 积极 | 2022-11-06 | |
Heparin sodium (Hep) 50% reduced dose | 憲觸構夢鹽襯選範襯糧(衊壓願鹽願鏇餘遞製鑰) = 網選觸觸蓋繭顧膚齋鹹 簾範鹽餘襯壓遞鬱獵餘 (憲衊鏇淵窪齋簾觸製憲 ) | ||||||
N/A | - | 14 | 餘觸鹹夢獵鑰蓋醖鬱遞(醖淵淵襯醖鏇鬱簾鏇艱) = 遞壓夢鹽衊淵願衊糧淵 構鑰顧顧衊廠壓觸艱艱 (願積遞顧積鏇選廠簾鑰 ) 更多 | 积极 | 2022-09-07 | ||
N/A | - | - | 網艱襯壓觸觸窪選壓鏇(壓繭醖蓋獵選遞窪鹽簾) = 範選廠餘選壓糧遞膚壓 顧齋憲繭網遞蓋鹽製觸 (襯製繭鹽艱餘選繭鹽構 ) 更多 | - | 2022-08-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用